Genetic association analysis of functional polymorphisms in neuronal nitric oxide synthase 1 gene (NOS1) and mood disorders and fluvoxamine response in major depressive disorder in the japanese population

Neuropsychobiology

Volumn 61, Issue 2, 2010, Pages 57-63

  Okumura, Takenori ^a   Kishi, Taro ^a   Okochi, Tomo ^a   Ikeda, Masashi ^a,d   Kitajima, Tsuyoshi ^a   Yamanouchi, Yoshio ^a   Kinoshita, Yoko ^a   Kawashima, Kunihiro ^a   Tsunoka, Tomoko ^a   Inada, Toshiya ^c   Ozaki, Norio ^b   Iwata, Nakao ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SEIWA HOSPITAL   (Japan)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Bipolar disorder; Fluvoxamine; Functional single nucleotide polymorphisms; Major depressive disorder; Neuronal nitric oxide synthase 1 gene

Indexed keywords

FLUVOXAMINE; NEURONAL NITRIC OXIDE SYNTHASE;

ADULT; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOOD DISORDER; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURED INTERVIEW; TREATMENT RESPONSE;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CHI-SQUARE DISTRIBUTION; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUVOXAMINE; GENE FREQUENCY; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; JAPAN; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE I; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 72049121241     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000265130     Document Type: Article

References (49)

1. Jesse CR, Bortolatto CF, Savegnago L, Rocha JB, Nogueira CW: Involvement of L-arginine- nitric oxide-cyclic guanosine monophosphate pathway in the antidepressantlike effect of tramadol in the rat forced swimming test. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1838-1843.
2. Rujescu D, Giegling I, Mandelli L, Schneider B, Hartmann AM, Schnabel A, Maurer K, Moller HJ, Serretti A: NOS-I and -III gene variants are differentially associated with facets of suicidal behavior and aggressionrelated traits. Am J Med Genet B Neuropsychiatr Genet 2008;147B:42-48.
3. Joca SR, Ferreira FR, Guimaraes FS: Modulation of stress consequences by hippocampal monoaminergic, glutamatergic and nitrergic neurotransmitter systems. Stress 2007; 10: 227-249.
4. Yao JK, Reddy RD: Metabolic investigation in psychiatric disorders. Mol Neurobiol 2005; 31: 193-203.
5. Pilc A, Chaki S, Nowak G, Witkin JM: Mood disorders: regulation by metabotropic glutamate receptors. Biochem Pharmacol 2008; 75: 997-1006.
6. Akyol O, Zoroglu SS, Armutcu F, Sahin S, Gurel A: Nitric oxide as a physiopathological factor in neuropsychiatric disorders. In Vivo 2004; 18: 377-390.
7. Bernstein HG, Heinemann A, Krell D, Mawrin C, Bielau H, Danos P, Diekmann S, Keilhoff G, Bogerts B, Baumann B: Further immunohistochemical evidence for impaired NO signaling in the hypothalamus of depressed patients. Ann NY Acad Sci 2002; 973: 91-93.
8. Chrapko WE, Jurasz P, Radomski MW, Lara N, Archer SL, Le Melledo JM: Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder. Biol Psychiatry 2004; 56: 129-134.
9. Savas HA, Herken H, Yurekli M, Uz E, Tutkun H, Zoroglu SS, Ozen ME, Cengiz B, Akyol O: Possible role of nitric oxide and adrenomedullin in bipolar affective disorder. Neuropsychobiology 2002; 45: 57-61. (Pubitemid 34224978)
10. Bryan-Lluka LJ, Papacostas MH, Paczkowski FA, Wanstall JC: Nitric oxide donors inhibit 5-hydroxytryptamine (5-HT) uptake by the human 5-HT transporter (SERT). Br J Pharmacol 2004; 143: 63-70.
11. Kilic F, Murphy DL, Rudnick G: A human serotonin transporter mutation causes constitutive activation of transport activity. Mol Pharmacol 2003; 64: 440-446.
12. Finkel MS, Laghrissi-Thode F, Pollock BG, Rong J: Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull 1996; 32: 653-658.
13. Jesse CR, Bortolatto CF, Savegnago L, Rocha JB, Nogueira CW: Involvement of L -arginine- nitric oxide-cyclic guanosine monophosphate pathway in the antidepressantlike effect of tramadol in the rat forced swimming test. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1838-1843.
14. Yanik M, Vural H, Tutkun H, Zoroglu SS, Savas HA, Herken H, Kocyigit A, Keles H, Akyol O: The role of the arginine-nitric oxide pathway in the pathogenesis of bipolar affective disorder. Eur Arch Psychiatry Clin Neurosci 2004; 254: 43-47.
15. Karolewicz B, Szebeni K, Stockmeier CA, Konick L, Overholser JC, Jurjus G, Roth BL, Ordway GA: Low nNOS protein in the locus coeruleus in major depression. J Neurochem 2004; 91: 1057-1066.
16. Spiacci A Jr, Kanamaru F, Guimaraes FS, Oliveira RM: Nitric oxide-mediated anxiolytic- like and antidepressant-like effects in animal models of anxiety and depression. Pharmacol Biochem Behav 2008; 88: 247-255.
17. Zhou QG, Hu Y, Hua Y, Hu M, Luo CX, Han X, Zhu XJ, Wang B, Xu JS, Zhu DY: Neuronal nitric oxide synthase contributes to chronic stress-induced depression by suppressing hippocampal neurogenesis. J Neurochem 2007; 103: 1843-1854.
18. Tang W, Huang K, Tang R, Zhou G, Fang C, Zhang J, Du L, Feng G, He L, Shi Y: Evidence for association between the 5 - flank of the NOS1 gene and schizophrenia in the Chinese population. Int J Neuropsychopharmacol 2008; 11: 1063-1071.
19. Shinkai T, Ohmori O, Hori H, Nakamura J: Allelic association of the neuronal nitric oxide synthase (NOS1) gene with schizophrenia. Mol Psychiatry 2002; 7: 560-563.
20. Reif A, Herterich S, Strobel A, Ehlis AC, Saur D, Jacob CP, Wienker T, Topner T, Fritzen S, Walter U, Schmitt A, Fallgatter AJ, Lesch KP: A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function. Mol Psychiatry 2006; 11: 286-300.
21. Fallin MD, Lasseter VK, Avramopoulos D, Nicodemus KK, Wolyniec PS, McGrath JA, Steel G, Nestadt G, Liang KY, Huganir RL, Valle D, Pulver AE: Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am J Hum Genet 2005; 77: 918-936.
22. Kawohl W, Giegling I, Mavrogiorgou P, Pogarell O, Mulert C, Moller HJ, Hegerl U, Rujescu D, Juckel G: Association of functional polymorphisms in NOS1 and NOS3 with loudness dependence of auditory evoked potentials. Int J Neuropsychopharmacol 2008; 11: 477-483. (Pubitemid 351744810)
23. Massey AE, Marsh VR, McAllister-Williams RH: Lack of effect of tryptophan depletion on the loudness dependency of auditory event related potentials in healthy volunteers. Biol Psychology 2004; 65: 137-145.
24. Oliveira RM, Guimaraes FS, Deakin JF: Expression of neuronal nitric oxide synthase in the hippocampal formation in affective disorders. Braz J Med Biol Res 2008; 41: 333-341.
25. Blackwood DH, Visscher PM, Muir WJ: Genetic studies of bipolar affective disorder in large families. Br J Psychiatry 2001; 41:s134-s136.
26. McGuffin P, Knight J, Breen G, Brewster S, Boyd PR, Craddock N, Gill M, Korszun A, Maier W, Middleton L, Mors O, Owen MJ, Perry J, Preisig M, Reich T, Rice J, Rietschel M, Jones L, Sham P, Farmer AE: Whole genome linkage scan of recurrent depressive disorder from the depression network study. Hum Mol Genet 2005; 14: 3337-3345.
27. Jones I, Jacobsen N, Green EK, Elvidge GP, Owen MJ, Craddock N: Evidence for familial cosegregation of major affective disorder and genetic markers flanking the gene for Darier's disease. Mol Psychiatry 2002; 7: 424-427.
28. Peveler R, Kendrick T: Selective serotonin reuptake inhibitors: thread trial may show way forward. BMJ 2005; 330: 420-421.
29. Saito S, Takahashi N, Ishihara R, Ikeda M, Suzuki T, Kitajima T, Yamanouchi Y, Iwata N, Yamada M, Yoshida K, Inada T, Ozaki N: Association study between vesicle-associated membrane protein 2 gene polymorphisms and fluvoxamine response in Japanese major depressive patients. Neuropsychobiology 2006; 54: 226-230.
30. Saur D, Vanderwinden JM, Seidler B, Schmid RM, De Laet MH, Allescher HD: Single-nucleotide promoter polymorphism alters transcription of neuronal nitric oxide synthase exon 1c in infantile hypertrophic pyloric stenosis. Proc Natl Acad Sci USA 2004; 101: 1662-1667.
31. Purcell S, Cherny SS, Sham PC: Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003; 19: 149-150.
32. Baron M: Genetic models of sex effect in unipolar affective illness. Acta Psychiatr Scand 1981; 64: 85-91.
33. Faraone SV, Lyons MJ, Tsuang MT: Sex differences in affective disorder: genetic transmission. Genet Epidemiol 1987; 4: 331-343.
34. Currier D, Mann MJ, Oquendo MA, Galfalvy H, Mann JJ: Sex differences in the familial transmission of mood disorders. J Affect Disord 2006; 95: 51-60.
35. Yu YW, Chen TJ, Wang YC, Liou YJ, Hong CJ, Tsai SJ: Association analysis for neuronal nitric oxide synthase gene polymorphism with major depression and fluoxetine response. Neuropsychobiology 2003; 47: 137-140.
36. Buttenschon HN, Mors O, Ewald H, Mc- Quillin A, Kalsi G, Lawrence J, Gurling H, Kruse TA: No association between a neuronal nitric oxide synthase (NOS1) gene polymorphism on chromosome 12q24 and bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2004; 124B:73-75.
37. Grasemann H, Yandava CN, Drazen JM: Neuronal NO synthase (NOS1) is a major candidate gene for asthma. Clin Exp Allergy 1999; 29(Suppl 4):39-41.
38. Reif A, Strobel A, Jacob CP, Herterich S, Freitag CM, Topner T, Mossner R, Fritzen S, Schmitt A, Lesch KP: A NOS-III haplotype that includes functional polymorphisms is associated with bipolar disorder. Int J Neuropsychopharmacol 2006; 9: 13-20.
39. Wang D, An SC, Zhang X: Prevention of chronic stress-induced depression-like behavior by inducible nitric oxide inhibitor. Neurosci Lett 2008; 433: 59-64.
40. Craddock N, Sklar P: Genetics of bipolar disorder: successful start to a long journey. Trends Genet 2009; 25: 99-105.
41. Hattori E, Toyota T, Ishitsuka Y, Iwayama Y, Yamada K, Ujike H, Morita Y, Kodama M, Nakata K, Minabe Y, Nakamura K, Iwata Y, Takei N, Mori N, Naitoh H, Yamanouchi Y, Iwata N, Ozaki N, Kato T, Nishikawa T, Kashiwa A, Suzuki M, Shioe K, Shinohara M, Hirano M, Nanko S, Akahane A, Ueno M, Kaneko N, Watanabe Y, Someya T, Hashimoto K, Iyo M, Itokawa M, Arai M, Nankai M, Inada T, Yoshida S, Kunugi H, Nakamura M, Iijima Y, Okazaki Y, Higuchi T, Yoshikawa T: Preliminary genome-wide association study of bipolar disorder in the Japanese population. Am J Med Genet B Neuropsychiatr Genet, E-pub ahead of print
42. Sklar P, Smoller JW, Fan J, Ferreira MA, Perlis RH, Chambert K, Nimgaonkar VL, Mc- Queen MB, Faraone SV, Kirby A, de Bakker PI, Ogdie MN, Thase ME, Sachs GS, Todd- Brown K, Gabriel SB, Sougnez C, Gates C, Blumenstiel B, Defelice M, Ardlie KG, Franklin J, Muir WJ, McGhee KA, MacIntyre DJ, McLean A, VanBeck M, McQuillin A, Bass NJ, Robinson M, Lawrence J, Anjorin A, Curtis D, Scolnick EM, Daly MJ, Blackwood DH, Gurling HM, Purcell SM: Whole-genome association study of bipolar disorder. Mol Psychiatry 2008; 13: 558-569.
43. O'Donovan MC, Craddock N, Norton N, Williams H, Peirce T, Moskvina V, Nikolov I, Hamshere M, Carroll L, Georgieva L, Dwy er S, Holmans P, Marchini JL, Spencer CC, Howie B, Leung HT, Hartmann AM, Moller HJ, Morris DW, Shi Y, Feng G, Hoffmann P, Propping P, Vasilescu C, Maier W, Rietschel M, Zammit S, Schumacher J, Quinn EM, Schulze TG, Williams NM, Giegling I, Iwata N, Ikeda M, Darvasi A, Shifman S, He L, Duan J, Sanders AR, Levinson DF, Gejman PV, Gejman PV, Sanders AR, Duan J, Levinson DF, Buccola NG, Mowry BJ, Freedman R, Amin F, Black DW, Silverman JM, Byerley WF, Cloninger CR, Cichon S, Nothen MM, Gill M, Corvin A, Rujescu D, Kirov G, Owen MJ: Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet 2008; 40: 1053-1055.
44. Lee BH, Kim YK: Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controls. Schizophr Res 2008; 104: 36-43.
45. Kishi T, Kitajima T, Ikeda M, Yamanouchi Y, Kinoshita Y, Kawashima K, Okochi T, Ozaki N, Iwata N: Association analysis of nuclear receptor Rev-erb alpha gene (NR1D1) with mood disorders in the Japanese population. Neurosci Res 2008; 62: 211-215.
46. Kishi T, Kitajima T, Tsunoka T, Ikeda M, Yamanouchi Y, Kinoshita Y, Kawashima K, Okochi T, Okumura T, Inada T, Ozaki N, Iwata N: Genetic association analysis of serotonin 2a receptor gene (HTR2A) with bipolar disorder and major depressive disorder in the Japanese population. Neurosci Res 2009; 64: 231-234.
47. Kishi T, Kitajima T, Ikeda M, Yamanouchi Y, Kinoshita Y, Kawashima K, Okochi T, Okumura T, Tsunoka T, Inada T, Ozaki N, Iwata N: Association study of clock gene (clock) and schizophrenia and mood disorders in the Japanese population. Eur Arch Psychiatry Clin Neurosci 2009; 259: 293-297.
48. Ikeda M, Takahashi N, Saito S, Aleksic B, Watanabe Y, Nunokawa A, Yamanouchi Y, Kitajima T, Kinoshita Y, Kishi T, Kawashima K, Hashimoto R, Ujike H, Inada T, Someya T, Takeda M, Ozaki N, Iwata N: Failure to replicate the association between NRG1 and schizophrenia using Japanese large sample. Schizophr Res 2008; 101: 1-8.
49. Kasper S, Dotsch M, Kick H, Vieira A, Moller HJ: Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. Eur Neuropsychopharmacol 1993; 3: 13-21.